Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Get Rating) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright decreased their price target on Regulus Therapeutics from $20.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday, April 21st.

Regulus Therapeutics Stock Up 3.8 %

NASDAQ RGLS opened at $1.37 on Wednesday. The company has a market cap of $26.69 million, a PE ratio of -0.75 and a beta of 1.56. Regulus Therapeutics has a 52 week low of $0.76 and a 52 week high of $3.40. The firm’s 50-day simple moving average is $1.20 and its two-hundred day simple moving average is $1.37.

Regulus Therapeutics (NASDAQ:RGLS – Get Rating) last released its quarterly earnings data on Thursday, March 23rd. The biopharmaceutical company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.09. As a group, equities research analysts anticipate that Regulus Therapeutics will post -1.53 EPS for the current year.

Hedge Funds Weigh In On Regulus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Federated Hermes Inc. purchased a new position in shares of Regulus Therapeutics during the first quarter worth about $8,656,000. Vanguard Group Inc. grew its stake in Regulus Therapeutics by 21.4% in the 1st quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 648,121 shares in the last quarter. Northern Trust Corp grew its stake in Regulus Therapeutics by 42.9% in the 1st quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 50,518 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Regulus Therapeutics by 498.2% during the 1st quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 111,100 shares in the last quarter. Finally, BlackRock Inc. lifted its holdings in shares of Regulus Therapeutics by 108.5% during the 3rd quarter. BlackRock Inc. now owns 45,614 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 23,738 shares during the last quarter. 55.47% of the stock is currently owned by institutional investors.

Regulus Therapeutics Company Profile

(Get Rating)

Regulus Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.